Prognostic value of c-Met in colorectal cancer: A meta-analysis

被引：60
作者：
Liu, Yan [1 ]
Yu, Xiao-Feng [1 ]
Zou, Jian [1 ]
Luo, Zi-Hua [1 ]
机构：
[1] Fudan Univ, Huadong Hosp, Dept Gastroenterol, Shanghai 200040, Peoples R China
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2015年 / 21卷 / 12期
关键词：
Colorectal cancer; Prognosis; c-Met; Meta-analysis; Overall survival; HEPATOCYTE GROWTH-FACTOR; II COLON-CANCER; CLINICAL-SIGNIFICANCE; LIVER METASTASES; EXPRESSION; STAGE; RECEPTOR; OVEREXPRESSION; AMPLIFICATION; COEXPRESSION;
D O I：
10.3748/wjg.v21.i12.3706
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AIM: To assess the prognostic value of c-Met status in colorectal cancer. METHODS: We conducted a search in PubMed, Web of Science, and the Cochrane Library covering all published papers up to July 2014. Only studies assessing survival in colorectal cancer by c-Met status were included. This meta-analysis was performed by using STATA11.0. RESULTS: Ultimately, 11 studies were included in this analysis. Meta-analysis of the hazard ratios (HR) indicated that patients with high c-Met expression have a significantly poorer overall survival (OR) (HR = 1.33, 95% CI: 1.06-1.59) and progression-free survival (PFS) (HR = 1.47, 95% CI: 1.03-1.91). Subgroup analysis showed a significant association between high c-Met expression and poorer overall survival in the hazard ratio reported (HR = 1.41, 95% CI: 1.08-1.74). CONCLUSION: The present meta-analysis indicated that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.
引用
收藏
页码：3706 / 3710
页数：5
相关论文
共 26 条
  • [1] Significance of micrometastases in colorectal cancer
    Feezor, RJ
    Copeland, EM
    Hochwald, SN
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (10) : 944 - 953
  • [2] Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases
    Fujita, S
    Sugano, K
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (06) : 378 - 383
  • [3] FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk
    Garouniatis, Alexandros
    Zizi-Sermpetzoglou, Adamantia
    Rizos, Spyros
    Kostakis, Alkiviadis
    Nikiteas, Nikolaos
    Papavassiliou, Athanasios G.
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (01) : 9 - 18
  • [4] The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer
    Ginty, Fiona
    Adak, Sudeshna
    Can, Ali
    Gerdes, Michael
    Larsen, Melinda
    Cline, Harvey
    Filkins, Robert
    Pang, Zhengyu
    Li, Qing
    Montalto, Michael C.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3814 - 3822
  • [5] Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?
    Inno, Alessandro
    Di Salvatore, Mariantonietta
    Cenci, Tonia
    Martini, Maurizio
    Orlandi, Armando
    Strippoli, Antonia
    Ferrara, Anna Maria
    Bagala, Cinzia
    Cassano, Alessandra
    Larocca, Luigi Maria
    Barone, Carlo
    [J]. CLINICAL COLORECTAL CANCER, 2011, 10 (04) : 325 - 332
  • [6] ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO
  • [7] 2-X
  • [8] Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome
    Kammula, Udal S.
    Kuntz, Eleanor J.
    Francone, Todd D.
    Zeng, Zhaoshi
    Shia, Jinru
    Landmann, Ron G.
    Paty, Philip B.
    Weiser, Martin R.
    [J]. CANCER LETTERS, 2007, 248 (02) : 219 - 228
  • [9] Kim SJ, 2003, CLIN CANCER RES, V9, P5161
  • [10] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Ohnishi, Hiroaki
    Masaki, Tadahiko
    Ohtsuka, Kouki
    Ohkura, Yasuo
    Furuse, Jyunji
    Watanabe, Takashi
    Sugiyama, Masanori
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 749 - 757
123